Nervous Disorder TRIZ Cases

Selective 5-HT2A and 5-HT2C inverse agonist compounds improve hallucination and delusion treatment while reducing cardiovascular side effects.

Salt and cocrystal forms of Compound 1 improve stability, purity, and bioavailability while enabling more reliable IDO drug manufacturing.

A targeted R1 substituent enables DRG-MAOB-1 to selectively inhibit MAO-B over MAO-A, supporting neurodegenerative treatment.

A mixed butyrate-MCFA triglyceride improves taste and odor while supporting butyrate delivery and ketone production with less GI intolerance.

Modified-release polymer matrices sustain T-type calcium channel modulation, extending therapeutic coverage while reducing peak concentration side effects.

A heterocyclic glucosylceramide synthase inhibitor reduces glycosphingolipid accumulation for lysosomal storage and neurodegenerative disease treatment.

Site-specific AAV capsid mutations improve CNS biodistribution and transduction efficiency, boosting brain-region cell expression versus wild type.

Antibodies against the non-phosphorylated tau 396-410 epitope help block extracellular toxic tau spread while sparing physiological tau function.

Clinical data identify older Parkinson's patients as better responders to istradefylline, reducing OFF time with fewer motor complications.

Selective α5-containing GABAA receptor modulation with benzodiazepine derivatives aims to improve cognition across CNS disorders.

Structural variation in GBA2 inhibitors improves enzyme selectivity and brain exposure, supporting glucosylceramide control in CNS and liver disease.

Activin A, bFGF, and amino acid signaling enrich Wnt-activated adipose stem cells, improving purity and safer neurodegenerative treatment.

A pH-activated Aβ dye lights up only in acidic phagosomes, separating internalized amyloid beta from surface-bound signal in microglia.

Blocking Rhes farnesylation with farnesyltransferase inhibitors restores autophagy, clears tau, and reduces neurofibrillary tangles.

Engineered CAR T cells target HER2, IL13Rα2, and EphA2 together to limit antigen escape and improve glioblastoma tumor control.

Using Cordyceps militaris extract, this case shows how pre-inhibiting hormone catabolism helps maintain testosterone and dihydrotestosterone levels.

Human neural stem cells extend treatment beyond hypothermia's narrow window to protect neonatal brain tissue and support recovery.

Selective EP4 antagonists modulate PGE2 signaling to preserve therapeutic effects while reducing the side effects linked to broad COX inhibition.

RAP inhibits LRP1 and pathological RhoA activation to drive OPC differentiation, boost remyelination, and slow MS progression.

Short peptides inhibit NF-κB more directly than TNF-α antagonists, enabling targeted gene modulation across inflammatory and cancer-related disorders.

Fenchol activates FFAR2 signaling to boost proteasome and lysosomal Aβ clearance, reducing neurotoxicity and supporting cognition in Alzheimer's disease.

Digestive enzyme therapy targets GI dysfunction linked to neurological and mental health symptoms, with fecal chymotrypsin guiding diagnosis.

Core-shell 3D printed implants with linear channels and neural stem cells guide axon regrowth while reducing foreign body response.

Liposome encapsulation stabilizes ionizable carotenoids and boosts bioavailability for treating sepsis, hypoxia, and ischemia.

Prodrug modification of A2B adenosine receptor antagonists improves aqueous formulation, plasma level reproducibility, and bioavailability.

A small-molecule PAR2 inhibitor, 1-PPA suppresses receptor RNA synthesis and binding activity to reduce inflammation and platelet aggregation.

Specific promoter, polyadenylation, and serotype choices raise AAV yield and HGF expression after intrathecal delivery.

A 3-9 mg daily nizubaglustat regimen improves function and lowers seizure burden while limiting severe side effects in lysosomal storage disorders.

Bile salts, sunflower oil, and carrier powders improve oral CBD absorption for epilepsy while supporting steady plasma levels and liver enzyme stability.

These derivatives treat fragile X and Rett syndrome deficits while avoiding serotonin, norepinephrine, and dopamine re-uptake inhibition.

An scFv linked to a CMA signal targets early misfolded TDP-43 for autophagic degradation, helping suppress neuronal cell death.

Selective benzimidazole STING antagonists inhibit interferon and ISG signaling to address autoimmune, inflammatory, and cardiovascular disorders.

Polymer-conjugated MMF injections control release and improve pharmacokinetic consistency while reducing GI side effects in RRMS and psoriasis.

Selective N-benzyl-2-phenoxybenzamides improve EP2 and EP4 receptor targeting for cancer, pain, inflammation, and kidney disease treatment.

Low-dose disulfiram and related compounds provide anxiolytic and antidepressant effects while reducing dependence and adverse effects.

Precise sodium and potassium R-beta-hydroxybutyrate ratios improve sustained ketosis, weight management, and blood glucose control.

Combining glutamate, dopamine, receptor, and BDNF-supporting agents improves memory and focus through coordinated multi-pathway action.

Small molecules modulate pre-mRNA splicing while bypassing oligonucleotide steric barriers and poor oral bioavailability.

Surface plasmon resonance apertures enable blood exosome marker detection for earlier, less invasive neurodegenerative diagnosis.

Uses syringaresinol to relieve chemotherapy- or nerve injury-related neuropathic pain while limiting side effects and preserving anticancer activity.

Phosphorothioate backbone conjugates carry non-cell-penetrating proteins into cells to disrupt STAT3 shuttling and trigger cancer cell apoptosis.

FAF1 inhibition with aminopyrazoles lowers alpha-synuclein aggregation and promotes autophagy for synucleinopathy treatment.

Novel substituted benzimidazole PPARα/δ agonists tune molecular substituents to improve pharmacokinetics without sacrificing metabolic activity.

User behavior data is used to detect default inhalation patterns and trigger notifications that keep aerosol ingredient delivery more consistent.

Specific levodopa, carbidopa, and entacapone ratios stabilize plasma levodopa levels to reduce wearing off and motor fluctuations.

Sodium octanoate promotes fatty acid oxidation when glucose use fails after cardiac arrest, improving CPR efficacy and limiting organ dysfunction.

Adding ondansetron to pramipexole reduces emesis and GI side effects, enabling higher antidepressant doses with better tolerability.

Small-molecule amide derivatives inhibit excessive NLRP3 activation to help treat inflammatory and degenerative diseases while preserving immune response.

Selective GABAA γ1 PAM benzodiazepines restore inhibitory signaling in ASD-related brain circuits while reducing sedation from non-selective drugs.

Type I PRMT inhibitors block arginine methylation in dipeptide repeat proteins to reduce neuronal toxicity linked to ALS and FTD.